Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.

Fengnian ZhaoJinge ZhaoXinyuan WeiYifu ShiNanwei XuSha ZhuJunru ChenGuangxi SunJindong DaiZhipeng WangXingming ZhangJiayu LiangXu HuHaoyang LiuJunjie ZhaoZhenhua LiuLing NiePeng-Fei Shen Ni Chen Hao Zeng

Published in: The Prostate (2024)

This study highlights KI67 positivity in prostate biopsy as a strong predictor of abiraterone efficacy in advanced PCa. These insights will assist clinicians in anticipating clinical outcomes and refining treatment decisions for PCa patients.

Keyphrases

prostate cancer
end stage renal disease
radical prostatectomy
ejection fraction
newly diagnosed
chronic kidney disease
palliative care
prognostic factors
neoadjuvant chemotherapy
signaling pathway
radiation therapy
lymph node
patient reported outcomes
replacement therapy